glp 1 overview Glucagon-like peptide in health and disease Mechanisms by which GLP-1 agonists
Description
doi: 10.1172/JCI57256 50 WiciskiMSochaMMalinowskiBWdkiewiczEWalczakMGrskiKet al
This combination of increased usage and expanded state coverage has increased Medicaid spending on GLP-1s for obesity to more than $500 million in October 2024 alone, with total expenditures reaching $3.5 billion over the past 12 months
Maintenance doses are typically 5 mg, 10 mg, or 15 mg, customized to your unique needs
Overall, the study offers insights into the financial trade-offs between GLP-1 s and bariatric surgery
Carris NW, Taylor JR, Gums JG
GLP-1s appear to run that cycle in reverse
